ArticleImmunity2024
Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks.
Open access · hybridAbstract read
In one paragraph
Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.Annals of medicine · 2026Review
- A conserved basic motif mediates membrane anchoring and TRAF2 recruitment across costimulatory TNFRs.The EMBO journal · 2026Article
- Comparative Transcriptomics Suggests that Breast Secretory Epithelium Reuses Gene Repertoires Conserved Across Vertebrates Beyond Mammals.Genome biology and evolution · 2026Article
- The Relationship and Mechanism of CD27 with Coronary Atherosclerotic Heart Disease.Cardiovascular drugs and therapy · 2026Review
- SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma.Oncogene · 2026Article
- Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial.Blood advances · 2026Article
- Spinal Cord Stimulation Alleviates Spinal Cord Injury-Induced Neuropathic Pain Via mNeurochemical research · 2026Article
- Erythropoietin prolongs graft survival in mice by counteracting trained immunity.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Regulators of CD8Nature reviews. Immunology · 2026Review
- Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy.Acta biochimica et biophysica Sinica · 2026Review
- Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy.Nature communications · 2026Article
- Targeting YAP1-CD70 axis potentiates the efficacy of anti-PD-1 therapy in prostate cancer.Biomarker research · 2026Article
- Integrating T cell signaling and metabolism to enhance T cell engager responses in solid tumors.Frontiers in immunology · 2026Review
- Control of breast cancer patient-derived xenografts by CD70-targeted HIT-CAR T cells.Frontiers in immunology · 2026Article
- Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy.Nature communications · 2025Article
- Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.Molecular cancer · 2025Review
- NaCl and urea modulate CD8+ T cell survival, renal accumulation, and response to BK virus.JCI insight · 2025Article
- CellNavi predicts genes directing cellular transitions by learning a gene graph-enhanced cell state manifold.Nature cell biology · 2025Article
- Quantifying HLA transcripts by genotype in chimeric mixtures at single-cell resolution.bioRxiv : the preprint server for biology · 2025Article
- CD8Science advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 4 institutions in 3 countries.
Carla A Jaeger-RuckstuhlTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: cjaeger@fredhutch.org.
Yun LoTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Elena FultonTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Olivia G WaltnerTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Tamer B ShabanehTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Sylvain SimonTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Pranav V MuthuramanTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Colin E CorrentiTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Oliver J NewsomHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Ian A EngstromHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Sami B KanaanTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Shruti S BhiseTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Jobelle M C PeraltaTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Raymond RuffTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Children's Hospital, Seattle, WA 98105, USA.
Jason P PriceTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Children's Hospital, Seattle, WA 98105, USA.
Sylvia M StullTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Andrew R StevensTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Grace BugosTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Mitchell G KluesnerHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Valentin VoilletVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Vishaka MuhunthanTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Fionnuala MorrishTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
James M OlsonTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Children's Hospital, Seattle, WA 98105, USA.
Raphaël GottardoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Statistics, University of Washington, Seattle, WA 98195, USA; Swiss Institute of Bioinformatics, University of Lausanne and Lausanne University Hospital, Lausanne 1011, Switzerland.
Jay F SarthySeattle Children's Hospital, Seattle, WA 98105, USA; Basic Science Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Steven HenikoffBasic Science Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Howard Hughes Medical Institute, Seattle, WA 98195, USA.
Lucas B SullivanHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Scott N FurlanTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Children's Hospital, Seattle, WA 98105, USA.
Stanley R RiddellTranslational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address: sriddell@fredhutch.org.
Fred Hutch Cancer Center · USSeattle Children's Hospital · USUniversity of Washington · USSeattle Children's Hospital · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MVIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL · 1985 to 2026
$128.4MTARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLSR01CA114536 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Sylvain Simon · 2005 to 2026
$8.4MImmunoregulatory Mechanisms of BiTE Efficacy in the Cold Neuroblastoma TMEU01CA281848 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI Vandana Kalia, JAMES M OLSON · 2023 to 2026
$3.5MCombinations of Synergistic Bispecific Human Antibodies: A Novel Strategy for the Treatment of NeuroblastomaU01CA232490 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI OLSON, JAMES M · 2018 to 2020
$2.4MNCI NIH HHS P01 CA018029NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA114536NCI NIH HHS U01 CA232490NCI NIH HHS U01 CA281848
Abstract
The interaction of the tumor necrosis factor receptor (TNFR) family member CD27 on naive CD8
Indexed as
CD28 AntigensGene Regulatory NetworksCD27 LigandCD8-Positive T-LymphocytesLymphocyte ActivationReceptors, Antigen, T-CellSignal TransductionTNF Receptor-Associated Factor 2Tumor Necrosis Factor Receptor Superfamily, Member 7CD27 LigandCD28 AntigensReceptors, Antigen, T-CellTNF Receptor-Associated Factor 2Tumor Necrosis Factor Receptor Superfamily, Member 7CAR-T cell therapyCD27CD8(+) T cellchimeric antigen receptorcostimulationmemory and effector fate determinationnaive T cell activationSHP-1 phosphatase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.